Date: 2013-09-18
Type of information: Licensing agreement
Compound: Adasuve® (Staccato® Loxapine)
Company: Medivir (Sweden) Ferrer (Spain)
Therapeutic area: CNS diseases - Mental diseases
Type agreement: licensing
distribution
commercialisation
Action mechanism:
Disease: schizophrenia, bipolar disease
Details: * On September 18, 2013, Ferrer and Medivir have entered a license and distribution agreement for the commercialization of Adasuve® (Staccato® Loxapine) in the Nordic region. In Europe, Adasuve® is approved for the treatment of mild to moderate agitation of patients with schizophrenia or bipolar disease. Under the terms of the agreement, Ferrer grants to Medivir the exclusive rights to promote, market, sell and distribute
Adasuve® in the Nordic region – including Denmark, Finland, Norway, Iceland and Sweden. Adasuve® is a hand-held inhaler designed to deliver the drug to the deep lung, providing rapid systemic delivery in a simple, non-invasive manner. Medivir thus becomes the exclusive supplier of this new treatment therapy for the treatment of mild to moderate agitation of patients with schizophrenia or bipolar disease. In return, Ferrer will receive an up-front payment upon signature, and milestone payments conditional upon cumulative sales performance.
Financial terms:
Latest news: * On April 30, 2014, Medivir has announced that Adasuve® now will be launched for the treatment of mild to moderate agitation of patients with schizophrenia or bipolar disorder. Medivir entered a license and distribution agreement for the commercialization of Adasuve® with Ferrer in September 2013. Adasuve® is Alexza's first commercial product, which was approved by the FDA in December 2012 and by the European Commission in February 2013. Teva Pharmaceuticals USA, Inc. is Alexza's commercial partner for Adasuve® in the U.S. Grupo Ferrer Internacional, S.A. is Alexza's commercial partner for Adasuve® in Europe, Latin America and the Commonwealth of Independent States countries. Adasuve® and Staccato® are registered trademarks of Alexza Pharmaceuticals, Inc.
